Login
$ZYME
$26.45 +$0.21 (0.8%) Live

$ZYME SEC Filings

Filed On Filing
16 Nov 2026 Form 4: Moore Paul Andrew, Chief Scientific Officer

Received 25,000 shares by exercise or conversion ($146K) · Sold 39,741 shares ($1.04M)

16 Nov 2026 8-K: Regulation FD Disclosure; Other Events

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

13 Nov 2026 144
09 Nov 2026 8-K/A: Financial Statements and Exhibits

As previously announced, on June 28, 2026, Zymeworks Inc. (“Zymeworks” or the “Company”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Theravance Biopharma, Inc. (“Theravance”) and Zymeworks Merger Sub 1, a w...

09 Nov 2026 10-Q
09 Nov 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Vancouver, British Columbia (November 9, 2026) – Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, to...

26 Oct 2026 ARS
26 Oct 2026 DEFA14A
26 Oct 2026 Proxy statement: annual meeting on December 15, 2026

CEO pay $6.6M, up 20% · say-on-pay vote

23 Oct 2026 8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure

Zymeworks Enters into an Exclusive Global License and Collaboration Agreement with Roche for ZW209, a Trispecific T cell Engager Targeting DLL3

16 Oct 2026 PRE 14A
09 Oct 2026 Form 4: Schayowitz Adam, EVP, Head of R&D

Received 37,037 shares by exercise or conversion · Sold 13,832 shares ($358K)

09 Oct 2026 144
23 Sep 2026 8-K: Entry into a Material Definitive Agreement; Completion of Acquisition or Disposition of Assets +2 more

NEITHER THIS DEBT INSTRUMENT NOR THE NOTES ISSUED IN CONNECTION HEREWITH HAVE BEEN REGISTERED UNDER THE SECURITIES ACT (AS DEFINED BELOW), OR ANY APPLICABLE STATE SECURITIES LAWS. SUCH SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT PURPOSE...

25 Aug 2026 8-K: Regulation FD Disclosure; Other Events

U.S. FDA Approves Ziihera® (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma

06 Aug 2026 10-Q
06 Aug 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Vancouver, British Columbia (August 6, 2026) – Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, toda...

06 Jul 2026 Form 4: Hollywood Mark, EVP & Chief Operating Officer

Received 939 shares as a grant or award ($20.9K)

29 Jun 2026 8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure

This AGREEMENT AND PLAN OF MERGER, dated as of June 28, 2026 (this “Agreement”), is entered into by and among Theravance Biopharma, Inc., an exempted company with limited liability incorporated under the Laws of the Cayman Islands (the “...

15 May 2026 Form 4: Schneider Paul R, EVP, General Counsel

Granted 178,000 Stock Option (Right to Buy) · Granted 119,000 Restricted Stock Unit

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support